| Name | Title | Contact Details |
|---|
Scarborough Community Care Access Centre is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Welbi is the fastest-growing resident experience platform for senior living communities. Our software platform helps senior living communities boost their resident experience by streamlining administrative processes, personalizing their programming, and keeping them ahead of changing resident needs. Welbi`s assessment tools and real-time analytics help resident experience teams gain a deep and holistic understanding of their residents. Combined with our powerful planning tools, our solution guides teams to effectively deliver and evaluate their programming to create more engaging experiences, ultimately boosting their bottom line.
Our mission as an organization is to serve our neighbors as expert, caring partners in their health. We do this by creating innovative, effective, affordable systems of care that our neighbors value. This is our promise to you. We call it The ChristianaCare Way. ChristianaCare has the most advanced health care technology available to help meet your needs. But more important than the technology is our commitment to partner with you to meet your individual needs. We want to care for you and help you live the healthy life you want to live.
Harborchase-Sterling Heights is a Sterling Heights, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.